Education
About Us
Working with TipRanks
Follow Us
Renovorx, Inc. (RNXT)
:RNXT
RNXT Stock Chart & Stats
$0.96
-$0.05(-3.65%)
At close: 4:00 PM EST
$0.96
-$0.05(-3.65%)
Day’s Range― - ―
52-Week Range$0.70 - $1.69
Previous CloseN/A
Volume39.72K
Average Volume (3M)302.47K
Market Cap
$35.18M
Enterprise Value$36.73M
Total Cash (Recent Filing)$10.04M
Total Debt (Recent Filing)$236.00K
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Apr 01, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding36,649,918
10 Day Avg. Volume187,651
30 Day Avg. Volume302,468
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)6.80
Price to Sales (P/S)708.18
P/FCF Ratio-3.33
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue39.58
Enterprise Value/Gross Profit58.40
Enterprise Value/Ebitda-4.59
Forecast
1Y Price Target
$5.63Price Target Upside486.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$1.28M
Bulls Say, Bears Say
Bulls Say
FDA ApprovalRenovoRx is now actively commercializing its FDA-cleared RenovoCath as a standalone FDA-cleared proprietary medical device.
Financial StabilityThe company had $12 million in cash and no debt, believed to be enough cash into late-2026.
Market PotentialPancreatic cancer is one of the deadliest cancers in the U.S. with very poor prognosis and outcomes, presenting a large market potential.
Bears Say
Net LossRenovoRx reported 3Q25 results with a net loss of ($2.9M) and ended the period with $10M in cash on the balance sheet.
Revenue PerformanceFor 3Q25, the company reported $0.27M in revenue, which was below the consensus estimate of $0.40M.
RenovoRx News
RNXT FAQ
What was Renovorx, Inc.’s price range in the past 12 months?
Renovorx, Inc. lowest stock price was $0.70 and its highest was $1.69 in the past 12 months.
What is Renovorx, Inc.’s market cap?
Renovorx, Inc.’s market cap is $35.18M.
When is Renovorx, Inc.’s upcoming earnings report date?
Renovorx, Inc.’s upcoming earnings report date is Apr 01, 2026 which is in 108 days.
How were Renovorx, Inc.’s earnings last quarter?
Renovorx, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.08 earnings per share for the quarter, the consensus estimate of -$0.08 by $0.
Is Renovorx, Inc. overvalued?
According to Wall Street analysts Renovorx, Inc.’s price is currently Undervalued.
Does Renovorx, Inc. pay dividends?
Renovorx, Inc. does not currently pay dividends.
What is Renovorx, Inc.’s EPS estimate?
Renovorx, Inc.’s EPS estimate is -0.08.
How many shares outstanding does Renovorx, Inc. have?
Renovorx, Inc. has 36,649,918 shares outstanding.
What happened to Renovorx, Inc.’s price movement after its last earnings report?
Renovorx, Inc. reported an EPS of -$0.08 in its last earnings report, expectations of -$0.08. Following the earnings report the stock price went down -22.68%.
Which hedge fund is a major shareholder of Renovorx, Inc.?
Currently, no hedge funds are holding shares in RNXT
RenovoRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.63 (486.46% Upside)
$5.63 (486.46% Upside)
Blogger Sentiment
Bullish
RNXT Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $27.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.27%
12-Months-Change
Fundamentals
Return on Equity
-146.61%
Trailing 12-Months
Asset Growth
11.71%
Trailing 12-Months
Company Description
Renovorx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
RNXT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
RenovoRx's earnings call highlights a strong commercial momentum with the expansion of their TAMP therapy and RenovoCath device, coupled with solid financial health and promising clinical trial progress. Despite being in the early stages of commercialization and facing a long sales cycle, the overall sentiment is positive due to the significant advancements and strategic positioning for future growth.View all RNXT earnings summariesRNXT Stock 12 Month Forecast
Average Price Target
$5.63
▲(486.46% Upside)
Technical Analysis
Ovid Therapeutics
―
Grace Therapeutics
―
Jasper Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
3.34% Insiders
5.54% Mutual Funds
11.83% Other Institutional Investors
75.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---